Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Coherus Oncology, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. Pacific Time, with the presentation accessible via webcast [1] - The webcast will be available for replay until February 13, 2026 [2] Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting various cancers [3] - The company's strategy focuses on growing sales of LOQTORZI in nasopharyngeal carcinoma (NPC) and advancing new indications for LOQTORZI in combination with its pipeline candidates and partners [3] Pipeline Details - Coherus' oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses to improve cancer treatment outcomes [4] - Tagmokitug, a selective cytolytic anti-CCR8 antibody, is currently in Phase 1b/2a studies for advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer [4] - Casdozokitug, a novel IL-27 antagonistic antibody, is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma [4]